Top Markets
Coin of the day
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMD
Peringkat dalam Saham #35178
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the... Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Harga Saham
$0.5225
Terakhir disinkronkan: 2026-08-14
Kapitalisasi Pasar
$4.32M
Perubahan (1 hari)
-1.60%
Perubahan (1 tahun)
-63.72%
Negara
IL
Perdagangan Galmed Pharmaceuticals Ltd. (GLMD)

Kategori

Riwayat hasil dividen untuk Galmed Pharmaceuticals Ltd. (GLMD)
Hasil dividen (TTM) dari Galmed Pharmaceuticals Ltd. (simbol saham: GLMD) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Galmed Pharmaceuticals Ltd. (GLMD) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing